U.S. Markets open in 56 mins

Achieve Life Sciences, Inc. (ACHV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.27-0.57 (-5.79%)
At close: 4:00PM EDT

9.49 +0.22 (2.37%)
Before hours: 8:00AM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.84
Open10.25
Bid8.05 x 800
Ask9.90 x 1200
Day's Range9.25 - 10.34
52 Week Range4.60 - 50.20
Volume342,593
Avg. Volume1,495,260
Market Cap33.253M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-12.35
Earnings DateNov 04, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.00
  • Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program
    PR Newswire

    Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program

    Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2020 financial results and provided an update on the cytisinicline clinical development program.

  • Zacks Small Cap Research

    ACHV: RAUORA: Cytisinicline’s Superior Side Effect Profile

    By John Vandermosten, CFA NASDAQ:ACHV On Monday, Achieve Life Sciences, Inc. (NASDAQ:ACHV) updated the investment community on the status of New Zealand’s RAUORA 1 study, which was expected to announce completion in the months leading up to the September SRNT conference. While full results were not provided, the study’s principal investigator did announce that cytisinicline was as good as

  • Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering
    CNW Group

    Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering

    SEATTLE and VANCOUVER, BC , June 29, 2020 /CNW/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 14,634,146 shares of common stock at a price of $0.41 per share in a registered direct offering, resulting in total gross proceeds of approximately $6 million , prior to deducting placement agent fees and estimated offering expenses. Lake Street Capital Markets LLC is acting as exclusive placement agent for the registered direct offering. The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-229019), which was declared effective by the United States Securities and Exchange Commission ("SEC") on February 11, 2019 .